# R4N PHARMA_V1 — Gate G6.39 Global Generics Valuation Calibration Evidence Sufficiency / Deferral Gate V1

**Status:** PROPOSAL ONLY / NOT ACTIVE  
**Primary subprofile:** `GLOBAL_GENERICS`  
**Metric:** `PHARMA_VALUATION_CONTEXT`  
**Canonical dimension:** `VALUATION`

## Purpose

G6.39 records that the parent Valuation methodology shape is valid and dimension-aligned, but the repository does not yet contain enough evidence to calibrate a Global Generics-specific numeric valuation curve.

This is a fail-closed deferral.

## Current calibration blockers

- Global Generics valuation calibration set not established.
- Reviewed Global Generics same-primary peer cohort not established.
- Self-history calibration not established.
- Peer-relative metric mix not established.
- Peer-relative bands not established.
- FCF corroboration method not established.
- Component-weight evidence not established.
- Final aggregation not established.

Therefore:

`globalSpecificCalibrationAvailable = false`

`numericValuationCurveReady = false`

`deferralRequired = true`

## What remains valid

The parent valuation methodology remains valid:

- self-history-relative valuation;
- peer-relative valuation;
- cash-flow corroboration;
- PE, EV/EBITDA and FCF yield evidence families;
- authoritative current market price;
- reviewed current earnings and cash inputs;
- business-model-aware peer cohort;
- explicit treatment of negative/non-meaningful denominators;
- acquisition/one-off normalization.

## What remains prohibited

- Domestic 40/40/20 weighting as fallback.
- Domestic 50/50 PE–EV/EBITDA peer blend as fallback.
- Domestic valuation bands as fallback.
- Missing-component renormalization.
- Hidden reweighting.
- Neutral substitution for missing evidence.

## Safety boundary

- Global Generics valuation calibration: **NO**
- Domestic calibration fallback: **NO**
- numeric Valuation curve: **NO**
- score execution: **NO**
- persistence: **NO**
- production mutation: **NO**
- deployment: **NO**
- PR #101 merge: **NO**

## Next step

After validation, close the Global Generics Valuation slice as explicitly incomplete/fail-closed and move to the next unresolved Global Generics family.
